[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:classic-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":135,"states":136},"Classic Hodgkin Lymphoma",20,16,[8,16,22,29,35,41,47,54,60,67,73,79,85,91,97,103,109,116,123,129],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04561206","Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:29.135998Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06745076","Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:29.013446Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06487624","An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors",[26],"Phase 1","2026-08-26T02:16:06.684983Z","2026-05-05T02:43:28.560873Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05039073","Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed\u002FRefractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.403517Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07021989","ctDNA-Guided Therapy for Relapsed\u002FRefractory Hodgkin Lymphoma",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:27.847086Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07275216","Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:27.480425Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT04685616","Brentuximab Vedotin in Early Stage Hodgkin Lymphoma",[51],"Phase 3","2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.405099Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05253495","Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma",[12],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:26.904491Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT03681561","Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma",[64],"Phase 1\u002FPhase 2","2026-08-26T02:16:55.892527Z","2026-05-05T02:43:26.677014Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06377540","MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma",[12],"2026-08-26T02:17:22.153941Z","2026-05-05T02:35:31.900755Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)",[64],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:29.025230Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06014502","Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors",[26],"2026-08-26T02:16:28.221034Z","2026-07-19T19:36:05.129130Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[64],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas",[26],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.120885Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05705531","A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma",[],"2026-08-26T02:19:11.399072Z","2026-05-13T02:55:06.372531Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07555210","Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy",[],"2026-08-26T02:16:59.895916Z","2026-05-13T02:55:06.722153Z",{"nct_id":110,"title":111,"phases":112,"status":113,"updated_at":114,"content_modified":115},"NCT06617286","CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma",[64],"NOT_YET_RECRUITING","2026-08-26T02:16:11.347936Z","2026-05-05T02:43:29.693368Z",{"nct_id":117,"title":118,"phases":119,"status":120,"updated_at":121,"content_modified":122},"NCT05723055","Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:20:46.845106Z","2026-05-05T02:43:28.628823Z",{"nct_id":124,"title":125,"phases":126,"status":120,"updated_at":127,"content_modified":128},"NCT05404945","Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above",[12],"2026-08-03T03:29:57.653021Z","2026-05-05T02:43:26.687439Z",{"nct_id":130,"title":131,"phases":132,"status":120,"updated_at":133,"content_modified":134},"NCT05362773","A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies",[26],"2026-08-03T03:16:06.901903Z","2026-05-05T02:43:29.384678Z",[],[137,141,145,149,152,156,159,162,166,169,172,175],{"state":138,"count":139,"slug":140},"California",7,"california",{"state":142,"count":143,"slug":144},"New York",6,"new-york",{"state":146,"count":147,"slug":148},"Illinois",5,"illinois",{"state":150,"count":147,"slug":151},"Texas","texas",{"state":153,"count":154,"slug":155},"Florida",4,"florida",{"state":157,"count":154,"slug":158},"Massachusetts","massachusetts",{"state":160,"count":154,"slug":161},"Missouri","missouri",{"state":163,"count":164,"slug":165},"Michigan",3,"michigan",{"state":167,"count":164,"slug":168},"Minnesota","minnesota",{"state":170,"count":164,"slug":171},"New Jersey","new-jersey",{"state":173,"count":164,"slug":174},"Pennsylvania","pennsylvania",{"state":176,"count":164,"slug":177},"Tennessee","tennessee"]